231 related articles for article (PubMed ID: 16188652)
1. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
Shaughnessy J
Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
[TBL] [Abstract][Full Text] [Related]
3. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
Zhan F; Colla S; Wu X; Chen B; Stewart JP; Kuehl WM; Barlogie B; Shaughnessy JD
Blood; 2007 Jun; 109(11):4995-5001. PubMed ID: 17303695
[TBL] [Abstract][Full Text] [Related]
4. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
Chang H; Qi X; Trieu Y; Xu W; Reader JC; Ning Y; Reece D
Br J Haematol; 2006 Nov; 135(4):486-91. PubMed ID: 16995883
[TBL] [Abstract][Full Text] [Related]
7. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?
Huang CW; Lin CY; Huang HY; Liu HW; Chen YJ; Shih DF; Chen HY; Juan CC; Ker CG; Huang CY; Li CF; Shiue YL
Ann Surg Oncol; 2010 Mar; 17(3):907-22. PubMed ID: 19866239
[TBL] [Abstract][Full Text] [Related]
8. Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications.
Bahmanyar M; Qi X; Chang H
Leuk Res; 2013 Dec; 37(12):1726-8. PubMed ID: 24169086
[TBL] [Abstract][Full Text] [Related]
9. CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma.
Martín-Ezquerra G; Salgado R; Toll A; Baró T; Mojal S; Yébenes M; Garcia-Muret MP; Solé F; Quitllet FA; Espinet B; Pujol RM
Histol Histopathol; 2011 Jan; 26(1):71-7. PubMed ID: 21117028
[TBL] [Abstract][Full Text] [Related]
10. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
Chang H; Yeung J; Xu W; Ning Y; Patterson B
Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
[TBL] [Abstract][Full Text] [Related]
11. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
13. CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour.
Salgado R; Toll A; Alameda F; Baró T; Martín-Ezquerra G; Sanmartín O; Martorell-Calatayud A; Salido M; Almenar S; Solé F; Pujol RM; Espinet B
Genes Chromosomes Cancer; 2010 Nov; 49(11):1054-61. PubMed ID: 20737481
[TBL] [Abstract][Full Text] [Related]
14. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
16. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
Shi L; Wang S; Zangari M; Xu H; Cao TM; Xu C; Wu Y; Xiao F; Liu Y; Yang Y; Salama M; Li G; Tricot G; Zhan F
Oncotarget; 2010 May; 1(1):22-33. PubMed ID: 20930946
[TBL] [Abstract][Full Text] [Related]
18. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
19. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
Bhatt KV; Hu R; Spofford LS; Aplin AE
Oncogene; 2007 Feb; 26(7):1056-66. PubMed ID: 16924241
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
Chang H; Ning Y; Qi X; Yeung J; Xu W
Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
